Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

10,710 total articles

Processa Pharmaceuticals CBO makes modest personal purchase; company hits Phase 2 enrollment milestone

Processa Pharmaceuticals CBO makes modest personal purchase; company hits Phase 2 enrollment milestone

Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, acquired 1,603 shares of common stock on March 31, 2026, a purchase valued at $4,063. The transaction leaves Lin with 3,356 shares directly and 1,740 shares indirectly via the Lin Family Trust Feb 4, 2024. Separately, Processa has finished enrollment and dosing for a planne…

Dolphin Entertainment CEO Increases Stake with $4,867 Purchase

Dolphin Entertainment CEO Increases Stake with $4,867 Purchase

Dolphin Entertainment CEO William O’Dowd IV acquired 3,100 shares of the company’s common stock on March 30, 2026, spending $4,867. The transaction brings his direct holdings to 456,290 shares, with additional indirect holdings through two wholly owned entities. The stock trades near its 52-week high amid volatility, and the company recently report…

CoreCivic CAO Disposes of $236,750 in Shares as Company Faces Operational and Valuation Headwinds

CoreCivic CAO Disposes of $236,750 in Shares as Company Faces Operational and Valuation Headwinds

CoreCivic Chief Administrative Officer Cole G. Carter sold 12,500 shares on April 1, 2026, for $18.94 each, generating $236,750 in proceeds and leaving him with 240,883 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. CoreCivic reported fourth-quarter 2025 adjusted EPS of $0.27 versus consensus $0.24, and revenue of $604…

Cytokinetics CEO Sells $499,724 in Stock as Shares Near Yearly High

Cytokinetics CEO Sells $499,724 in Stock as Shares Near Yearly High

Cytokinetics President and CEO Robert I. Blum sold 7,500 shares on April 1, 2026, at $66.63 per share for a total of $499,724. The sale occurred as the stock traded close to its 52-week high following a 76% gain over the past year. Analysts have issued several recent updates and raised price targets tied to the prospects for Myqorzo (aficamten) and…

Vitesse Energy Director Adds 10,000 Shares as Company Navigates Earnings Miss and Leadership Change

Vitesse Energy Director Adds 10,000 Shares as Company Navigates Earnings Miss and Leadership Change

Vitesse Energy director Dan O’Leary purchased 10,000 shares on March 31, 2026, at $18.56 per share, bringing his direct holdings to 33,789 shares. The transaction occurred as the stock traded near a 52-week low and the company reported a large EPS shortfall alongside a revenue beat, implemented commodity hedges covering much of 2026 production, and…

Maze Therapeutics CSBO Sells $220,018 of Stock After Exercising Options; Company Posts Promising Phase 2 Data

Maze Therapeutics CSBO Sells $220,018 of Stock After Exercising Options; Company Posts Promising Phase 2 Data

Atul Dandekar, Maze Therapeutics' Chief Strategy and Business Officer, sold 7,500 shares of the company on March 30, 2026, for $220,018 and exercised options to buy 7,500 shares at $10.42 the same day. The transactions leave him with 10,503 shares and were carried out under a Rule 10b5-1 plan established in September 2025. Maze recently disclosed P…

CoreWeave Development Chief Disposes $9.9M in CRWV Shares; Simultaneous Class B Conversions Executed

CoreWeave Development Chief Disposes $9.9M in CRWV Shares; Simultaneous Class B Conversions Executed

CoreWeave Chief Development Officer Brannin McBee executed roughly $9.9 million in sales of Class A Common Stock on March 30, 2026, across several blocks and at prices between $67.67 and $75.19 per share. The sales - made directly, via an irrevocable trust, and through shares held by a spouse - were conducted under a pre-arranged Rule 10b5-1 plan a…

Simon Property Director Reinvests Dividends, Buys $14,887 in SPG Stock; Leadership Shift Announced

Simon Property Director Reinvests Dividends, Buys $14,887 in SPG Stock; Leadership Shift Announced

Peggy Roe, a director at Simon Property Group Inc., purchased 81 shares through dividend reinvestment on March 31, 2026, for $14,887. The transaction coincides with the company’s announcement of the death of longtime leader David Simon and the appointment of Eli Simon as CEO and president, alongside an amendment to the firm’s $5 billion revolving c…

Simon Property Director Smith Increases Stake via Dividend Reinvestment; Company Navigates Leadership Shift and Credit Facility Update

Simon Property Director Smith Increases Stake via Dividend Reinvestment; Company Navigates Leadership Shift and Credit Facility Update

Simon Property Group Director Smith Daniel C. purchased 355 shares of SPG common stock on March 31, 2026, through dividend reinvestment, raising his direct holdings to 33,035 shares. The transaction, executed at $183.80 per share for $65,249, occurred amid a leadership transition following the death of longtime chairman and CEO David Simon and adju…

Director Frank Joel L. Buys $2,508 of Mid Penn Bancorp Stock; Bank Reports Earnings and Acquisition Activity

Director Frank Joel L. Buys $2,508 of Mid Penn Bancorp Stock; Bank Reports Earnings and Acquisition Activity

Director Frank Joel L. purchased 78 shares of Mid Penn Bancorp Inc (NASDAQ: MPB) on March 31, 2026, via the company’s Director Stock Purchase Plan for $2,508. The transaction increases his direct holdings to 9,408.499 shares plus 1,945 shares of restricted common stock. The regional bank recently reported a 47% rise in fourth-quarter 2025 net incom…